Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 161, Issue -, Pages 4-14Publisher
ELSEVIER
DOI: 10.1016/j.ejpb.2021.02.002
Keywords
Exosomes; Pancreatic cancer; Cancer therapy; Delivery system
Categories
Funding
- Portuguese Science and Technology Foundation (FCT)
- European Regional Development Fund (FEDER) Competitiveness and Internationalization Operational Program (COMPETE2020)
- own Revenues of the University of Coimbra [POCI-01-0247-FEDER-033532, CENTRO010145FEDER00001220172020]
- FCT/FEDER/COMPETE2020 [UIDB/04501/2020]
- FCT [PD/BDE/135076/2017]
- Fundação para a Ciência e a Tecnologia [PD/BDE/135076/2017] Funding Source: FCT
Ask authors/readers for more resources
Pancreatic cancer is a deadly cancer with low survival rates and often goes undetected until late stages. Despite extensive research, the 5-year survival rate has not significantly improved. However, new therapeutic approaches using exosomes show promise in delivering anti-cancer drugs effectively and with less toxicity.
Pancreatic cancer (PC) is one of the deadliest cancers with a very short rate of survival and commonly without symptoms in its early stage. This absence of symptoms can lead to a late diagnosis associated with an advanced metastasis process, for which therapy is not effective. Although with extensive research in this field, the 5-year survival rate has not increased significantly. Notwithstanding, novel insights on risk factors, genetic mutations and molecular mechanisms pave the way for novel therapeutics that urge with a significant part of PC patients presenting resistance to chemotherapy treatments. Exosomes are presented as a promising strategy, working as delivery systems, since they can transport and release their cargoes after fusing with the membrane of pancreatic cells. Exosomes present advantages over liposomes, being less toxic and reaching higher levels in the bloodstream, working as molecule carriers that can inhibit oncogenes, activating tumor suppressor genes and inducing immune responses as well as controlling cell growth. This review intends to provide an overview about the scientific and clinical studies regarding the entire process, from isolation and purification of exosomes, to their design and transformation into anti-oncogenic drug delivering systems, particularly to target PC cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available